Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-12

Study Completion Date

2025-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OSF is a widespread health issue in Asian countries, notably Pakistan, linked to the consumption of pan, chalia, and gutka, affecting a rising number of young individuals as an epidemic. This condition significantly impairs oral function, resulting in ulcers and chronic lesions, often progressing to oral cancer. Current treatments focus on symptom relief and halting disease progression. This study explores the repurposing of metformin, an FDA-approved drug with antifibrotic properties, for OSF treatment. Our objective is to unveil its therapeutic potential and comprehend its impact on the dysregulated signaling pathways associated with OSF. This research offers promising insights for an enhanced management approach, providing hope for those grappling with this debilitating condition

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Biomarker Levels Improvement in Poly Cystic Ovarian Syndrome: Impact of Metformin Compared to Healthy Controls

NCT06479434

Polycystic Ovary Syndrome Insulin Resistance

COMPLETED NA

Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome

NCT03117517

Polycystic Ovarian Syndrome

COMPLETED EARLY_PHASE1

Effect of Unani Medicine for the Management of Anomalies Associated With Polycystic Ovarian Syndrome

NCT06199544

Comparative Study

RECRUITING PHASE1

Comparison of Probiotics, Metformin & Their Combination Therapy in the Treatment of PCOS

NCT04009603

Polycystic Ovary Syndrome

COMPLETED NA

Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.

NCT05952349

PCO

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OSF stands as a persistent inflammatory and potentially malignant condition affecting the oral cavity, marked by progressive fibrosis of the oral mucosa. The spectrum of its manifestations spans from initial inflammation to the gradual emergence of fibrous bands, leading to restricted mouth opening and mucosal rigidity. Common symptoms encompass burning sensations, difficulty in swallowing, and alterations in taste perception. This health concern has gained prominence in Pakistan, experiencing a worrisome surge in prevalence from 8.3/105 to 16.2/105 in recent years. Formerly confined to Southeast Asia, OSF has now transcended borders, manifesting in Asian immigrant communities in Britain and America, evolving into a global oral potential malignant disorder (OPMD) with a malignant rate of 9.13% .

Presently, the corticosteroid-based approach effectively reduces inflammation in OSF but falls short in addressing the underlying molecular mechanisms contributing to fibrosis. Furthermore, the prolonged use of corticosteroids raises concerns about adverse effects, including mucosal atrophy and compromised tissue integrity. This study aims to investigate the potential of metformin, a recognized emerging drug for treating fibrosis, and its anti-fibrotic properties in various organs. The established safety profile of metformin adds an advantageous aspect to its potential applications.

Numerous studies indicate that metformin exhibits anti-fibrotic effects by inhibiting TGF-β1 production, reducing phosphorylation and nuclear translocation of Smad2/3. Additionally, metformin inhibits Smad2/3 phosphorylation independently and activates AMPK, hindering Smad3 phosphorylation. The impact on reactive oxygen species (ROS) generation moderates TGF-β1-induced Smad2/3 phosphorylation and myofibroblast differentiation.Metformin has shown promise in hindering collagen production and promoting trans differentiation in various organ, including the lung, kidney, heart and adipose tissue. A clinical trial reported metformin therapy's impact on postmenopausal ovaries, patients with type 2 diabetes mellitus (T2DM) exhibited isotropic collagen organization and reduced fibrosis during oophorectomy.The observed risk reduction for ovarian cancer in T2DM women using metformin suggests its potential as an ovarian cancer prophylaxis. Despite conflicting clinical trial results in liver fibrosis, metformin consistently improves hepatocyte damage and inflammation. Clinical trials have explored the role of metformin antitumor activity when combined with conventional chemotherapeutic drugs and in idiopathic pulmonary fibrosis it inhibits TGFβ1, suppressing collagen formation, activating PPARγ signaling and inducing lipogenic differentiation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Submucous Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1\. In Vitro (Cell Line) Study Design: Experimental in vitro study using OSF cell lines.

Groups:

* Metformin-treated
* Control (untreated)
* Vehicle control Clinical Trial Study Design: A pilot Randomized Controlled Trial (RCT) translating the in vitro findings into a clinical setting. It would be a single-blind, placebo-controlled designAll groups will undergo a 24-week intervention phase. Group 1 will receive standard treatment including topical cream betamethasone thrice daily and Pentoxifylline tablet 400 mg twice daily. Group 2 will receive Metformin 500 mg thrice daily. Group 3 will receive topical cream metformin thrice daily. All groups will be instructed to perform a stick mouth opening exercise twice daily, alternating sides, holding the stick for 10 minutes on each side, with a 10-minute rest in between. All groups will be single blinded to the intervention.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

It would be a single-blind, placebo-controlled design

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard

Group 1: Standard treatment with topical cream betamethasone and Pentoxifylline tablet.

Group Type ACTIVE_COMPARATOR

betamethasone dipropionate

Intervention Type DRUG

Group 1will recieve topical cream betamethasone thrice daily

Pentoxifylline

Intervention Type DRUG

Group 1 will receive Pentoxifylline tablet 400 mg twice daily

MetforminO

Metformin 500 mg thrice daily.

Group Type EXPERIMENTAL

Metformin Hydrochloride

Intervention Type DRUG

Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

MetforminT

Topical cream metformin thrice daily

Group Type EXPERIMENTAL

Metformin Hydrochloride

Intervention Type DRUG

Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin Hydrochloride

Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

Intervention Type DRUG

betamethasone dipropionate

Group 1will recieve topical cream betamethasone thrice daily

Intervention Type DRUG

Pentoxifylline

Group 1 will receive Pentoxifylline tablet 400 mg twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glucophage Betnovate Trental

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with OSF- palpable bands on oral examination
2. Patients with limited mouth opening due to OSF
3. Patients who have not received any treatment for OSF in the previous three months
4. Patients with habits of pan, Chalia, Ghutka
5. Age group between 18 and 45 years

Exclusion Criteria

1. Patients presenting with both OSCC and OSF
2. Patients with limited mouth opening due to impaction of the third molar (impaction of third molar results in limited mouth opening hence such patients are excluded since limited mouth opening due to third molar impaction can be mistaken for OSF).
3. Patients with limited mouth opening due to temporomandibular joint disorder (temporomandibular joint disorders can limit the ability of patient to open their mouth and hence can be mistaken for OSF)
4. Any history of Metformin intolerance or contraindications.
5. Presence of other severe medical conditions along with drug therapy.
6. Pregnancy or lactation.
7. Participation in other clinical trials concurrently.
8. Inability to provide informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No